Iron has emerged as a significant cause of neurotoxicity in several neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), sporadic Creutzfeldt-Jakob disease (sCJD), and others. In some cases, the underlying cause of iron mis-metabolism is known, while in others, our understanding is, at best, incomplete. Recent evidence implicating key proteins involved in the pathogenesis of AD, PD, and sCJD in cellular iron metabolism suggests that imbalance of brain iron homeostasis associated with these disorders is a direct consequence of disease pathogenesis. A complete understanding of the molecular events leading to this phenotype is lacking partly because of the complex regulation of iron homeostasis within the brain. Since systemic organs and the brain share several iron regulatory mechanisms and iron-modulating proteins, dysfunction of a specific pathway or selective absence of iron-modulating protein(s) in systemic organs has provided important insights into the maintenance of iron homeostasis within the brain. Here, we review recent information on the regulation of iron uptake and utilization in systemic organs and within the complex environment of the brain, with particular emphasis on the underlying mechanisms leading to brain iron mis-metabolism in specific neurodegenerative conditions. Mouse models that have been instrumental in understanding systemic and brain disorders associated with iron mis-metabolism are also described, followed by current therapeutic strategies which are aimed at restoring brain iron homeostasis in different neurodegenerative conditions. We conclude by highlighting important gaps in our understanding of brain iron metabolism and mis-metabolism, particularly in the context of neurodegenerative disorders. Antioxid. Redox Signal. 20, 1324–1363.
AbeliovichA, SchmitzY, FarinasI, Choi-LundbergD, HoWH, CastilloPE, ShinskyN, VerdugoJMG, ArmaniniM, RyanA, HynesM, PhillipsH, SulzerD, and RosenthalA. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25: 239–252, 2000.
2.
AbibRT, Quincozes-SantosA, ZanottoC, Zeidan-ChuliaF, LunardiPS, GoncalvesCA, and GottfriedC. Genoprotective effects of the green tea-derived polyphenol/epicatechin gallate in C6 astroglial cells. J Med Food, 13: 1111–1115, 2010.
3.
AdinolfiS, TrifuoggiM, PolitouAS, MartinS, and PastoreA. A structural approach to understanding the iron-binding properties of phylogenetically different frataxins. Hum Mol Genet, 11: 1865–1877, 2002.
4.
AdlardPA, ChernyRA, FinkelsteinDI, GautierE, RobbE, CortesM, VolitakisI, LiuX, SmithJP, PerezK, LaughtonK, LiQX, CharmanSA, NicolazzoJA, WilkinsS, DelevaK, LynchT, KokG, RitchieCW, TanziRE, CappaiR, MastersCL, BarnhamKJ, and BushAI. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A beta. Neuron, 59: 43–55, 2008.
5.
AguilaniuH, GustafssonL, RigouletM, and NystromT. Asymmetric inheritance of oxidatively damaged proteins during cytokinesis. Science, 299: 1751–1753, 2003.
6.
AguirreP, UrrutiaP, TapiaV, VillaM, ParisI, Segura-AguilarJ, and NunezMT. The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals, 25: 795–803, 2012.
7.
AguzziA, BaumannF, and BremerJ. The prion's elusive reason for being. Annu Rev Neurosci, 31: 439–477, 2008.
8.
AguzziA and FalsigJ. Prion propagation, toxicity and degradation. Nat Neurosci, 15: 936–939, 2012.
9.
AhmedI, LiangY, SchoolsS, DawsonVL, DawsonTM, and SavittJM. Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci, 32: 16503–16509, 2012.
10.
Al-MahdawiS, PintoRM, VarshneyD, LawrenceL, LowrieMB, HughesS, WebsterZ, BlakeJ, CooperJM, KingR, and PookMA. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics, 88: 580–590, 2006.
11.
AllikmetsR, RaskindWH, HutchinsonA, SchueckND, DeanM, and KoellerDM. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet, 8: 743–749, 1999.
12.
AloriaK, SchilkeB, AndrewA, and CraigEA. Iron-induced oligomerization of yeast frataxin homologue Yfh1 is dispensable in vivo. EMBO Rep, 5: 1096–1101, 2004.
13.
AltamuraS and MuckenthalerMU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis, 16: 879–895, 2009.
14.
AmitT, Avramovich-TiroshY, YoudimMB, and MandelS. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J, 22: 1296–1305, 2008.
15.
AndersonGJ, LesuisseE, DancisA, RomanDG, LabbeP, and KlausnerRD. Ferric iron reduction and iron assimilation in Saccharomyces cerevisiae. J Inorg Biochem, 47: 249–255, 1992.
16.
AndriopoulosB, CorradiniE, XiaY, FaasseSA, ChenSZ, GrgurevicL, KnutsonMD, PietrangeloA, VukicevicS, LinHY, and BabittJL. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet, 41: 482–487, 2009.
17.
ArduinoDM, EstevesAR, CortesL, SilvaDF, PatelB, GrazinaM, SwerdlowRH, OliveiraCR, and CardosoSM. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum Mol Genet, 21: 4680–4702, 2012.
18.
ArmstrongCM, BernhardtPV, ChinP, and RichardsonDR. Structural Variations and Formation Constants of First-Row Tr ansition Metal Complexes of Biologically Active Aroylhydrazones. Eur J Inorg Chem, 6: 1145–1156, 2003.
19.
Aronoff-SpencerE, BurnsCS, AvdievichNI, GerfenGJ, PeisachJ, AntholineWE, BallHL, CohenFE, PrusinerSB, and MillhauserGL. Identification of the Cu2+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry, 39: 13760–13771, 2000.
20.
ArosioP, IngrassiaR, and CavadiniP. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta, 1790: 589–599, 2009.
21.
ArosioP and LeviS. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta, 1800: 783–792, 2010.
22.
AtamnaH. Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev, 3: 303–318, 2004.
23.
Avramovich-TiroshY, Bar-AmO, AmitT, YoudimMB, and WeinrebO. Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res, 7: 300–306, 2010.
24.
BabcockM, de SilvaD, OaksR, Davis-KaplanS, JiralerspongS, MonterminiL, PandolfoM, and KaplanJ. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science, 276: 1709–1712, 1997.
25.
BaraibarMA, BarbeitoAG, MuhoberacBB, and VidalR. Iron-mediated aggregation and a localized structural change characterize ferritin from a mutant light chain polypeptide that causes neurodegeneration. J Biol Chem, 283: 31679–31689, 2008.
26.
BaraibarMA, BarbeitoAG, MuhoberacBB, and VidalR. A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage. Free Radic Bio Med, 52: 1692–1697, 2012.
27.
BaraibarMA, MuhoberacBB, GarringerHJ, HurleyTD, and VidalR. Unraveling of the E-helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration. J Biol Chem, 285: 1950–1956, 2010.
28.
BarbeitoAG, GarringerHJ, BaraibarMA, GaoX, ArredondoM, NunezMT, SmithMA, GhettiB, and VidalR. Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J Neurochem, 109: 1067–1078, 2009.
29.
BarbeitoAG, LevadeT, DelisleMB, GhettiB, and VidalR. Abnormal iron metabolism in fibroblasts from a patient with the neurodegenerative disease hereditary ferritinopathy. Mol Neurodegener, 5: 50, 2010.
30.
BarnhamKJ and BushAI. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol, 12: 222–228, 2008.
31.
BarnhamKJ, McKinstryWJ, MulthaupG, GalatisD, MortonCJ, CurtainCC, WilliamsonNA, WhiteAR, HindsMG, NortonRS, BeyreutherK, MastersCL, ParkerMW, and CappaiR. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem, 278: 17401–17407, 2003.
32.
BaronGS, MagalhaesAC, PradoMA, and CaugheyB. Mouse-adapted scrapie infection of SN56 cells: greater efficiency with microsome-associated versus purified PrP-res. J Virol, 80: 2106–2117, 2006.
33.
BaroneE, Di DomenicoF, CeniniG, SultanaR, CiniC, PreziosiP, PerluigiM, MancusoC, and ButterfieldDA. Biliverdin reductase—a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta, 1812: 480–487, 2011.
34.
BaroneE, Di DomenicoF, CeniniG, SultanaR, CocciaR, PreziosiP, PerluigiM, MancusoC, and ButterfieldDA. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis, 25: 623–633, 2011.
35.
BaroneE, Di DomenicoF, SultanaR, CocciaR, MancusoC, PerluigiM, and ButterfieldDA. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med, 52: 2292–2301, 2012.
36.
BasuS, MohanML, LuoX, KunduB, KongQ, and SinghN. Modulation of proteinase K-resistant prion protein in cells and infectious brain homogenate by redox iron: implications for prion replication and disease pathogenesis. Mol Biol Cell, 18: 3302–3312, 2007.
37.
BaumL, LamCW, CheungSK, KwokT, LuiV, TsohJ, LamL, LeungV, HuiE, NgC, WooJ, ChiuHF, GogginsWB, ZeeBC, ChengKF, FongCY, WongA, MokH, ChowMS, HoPC, IpSP, HoCS, YuXW, LaiCY, ChanMH, SzetoS, ChanIH, and MokV. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol, 28: 110–113, 2008.
38.
BeardJL, WiesingerJA, LiN, and ConnorJR. Brain iron uptake in hypotransferrinemic mice: influence of systemic iron status. J Neurosci Res, 79: 254–261, 2005.
39.
BeckerEM, GreerJM, PonkaP, and RichardsonDR. Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood, 99: 3813–3822, 2002.
40.
BekriS, KispalG, LangeH, FitzsimonsE, TolmieJ, LillR, and BishopDF. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood, 96: 3256–3264, 2000.
41.
Ben-ShacharD, RiedererP, and YoudimMB. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem, 57: 1609–1614, 1991.
42.
BercianoJ, InfanteJ, GarciaA, PoloJM, VolpiniV, and CombarrosO. Very late-onset Friedreich's ataxia with minimal GAA1 expansion mimicking multiple system atrophy of cerebellar type. Mov Disord, 20: 1643–1645, 2005.
43.
BidichandaniSI, AshizawaT, and PatelPI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet, 62: 111–121, 1998.
44.
BiederbickA, StehlingO, RosserR, NiggemeyerB, NakaiY, ElsasserHP, and LillR. Role of human mitochondrial Nfs1 in cytosolic iron-sulfur protein biogenesis and iron regulation. Mol Cell Biol, 26: 5675–5687, 2006.
45.
BilgicB, PfefferbaumA, RohlfingT, SullivanEV, and AdalsteinssonE. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage, 59: 2625–2635, 2012.
46.
BishopDF, TchaikovskiiV, HoffbrandAV, FraserME, and MargolisS. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the beta-subunit of succinyl-CoA synthetase (SUCLA2). J Biol Chem, 287: 28943–28955, 2012.
47.
BleackleyMR and MacgillivrayRT. Transition metal homeostasis: from yeast to human disease. Biometals, 24: 785–809, 2011.
48.
BoddaertN, Le Quan SangKH, RotigA, Leroy-WilligA, GalletS, BrunelleF, SidiD, ThalabardJC, MunnichA, and CabantchikZI. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood, 110: 401–408, 2007.
49.
BonifatiV, RizzuP, van BarenMJ, SchaapO, BreedveldGJ, KriegerE, DekkerMC, SquitieriF, IbanezP, JoosseM, van DongenJW, VanacoreN, van SwietenJC, BriceA, MecoG, van DuijnCM, OostraBA, and HeutinkP. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299: 256–259, 2003.
50.
BorieC, GaspariniF, VerpillatP, BonnetAM, AgidY, HetetG, BriceA, DurrA, and GrandchampB. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol, 249: 801–804, 2002.
51.
Bou-AbdallahF, SantambrogioP, LeviS, ArosioP, and ChasteenND. Unique iron binding and oxidation properties of human mitochondrial ferritin: a comparative analysis with human H-chain ferritin. J Mol Biol, 347: 543–554, 2005.
52.
BowenBJ and MorganEH. Anemia of the Belgrade rat: evidence for defective membrane transport of iron. Blood, 70: 38–44, 1987.
53.
BradburyMW. Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem, 69: 443–454, 1997.
54.
BradleyJL, BlakeJC, ChamberlainS, ThomasPK, CooperJM, and SchapiraAH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet, 9: 275–282, 2000.
55.
BrazierMW, VolitakisI, KvasnickaM, WhiteAR, UnderwoodJR, GreenJE, HanS, HillAF, MastersCL, and CollinsSJ. Manganese chelation therapy extends survival in a mouse model of M1000 prion disease. J Neurochem, 114: 440–451, 2010.
56.
Bridwell-RabbJ, WinnAM, and BarondeauDP. Structure-function analysis of Friedreich's ataxia mutants reveals determinants of frataxin binding and activation of the Fe-S assembly complex. Biochemistry, 50: 7265–7274, 2011.
57.
BrownDR, QinK, HermsJW, MadlungA, MansonJ, StromeR, FraserPE, KruckT, von BohlenA, Schulz-SchaefferW, GieseA, WestawayD, and KretzschmarH. The cellular prion protein binds copper in vivo. Nature, 390: 684–687, 1997.
58.
BulteauAL, O'NeillHA, KennedyMC, Ikeda-SaitoM, IsayaG, and SzwedaLI. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science, 305: 242–245, 2004.
59.
BurnJ and ChinneryPF. Neuroferritinopathy. Semin Pediatr Neurol, 13: 176–181, 2006.
60.
BushAI. The metallobiology of Alzheimer's disease. Trends Neurosci, 26: 207–214, 2003.
61.
BushAI and CurtainCC. Twenty years of metallo-neurobiology: where to now?. Eur Biophys J, 37: 241–245, 2008.
62.
ButlerEK, VoigtA, LutzAK, ToegelJP, GerhardtE, KarstenP, FalkenburgerB, ReinartzA, WinklhoferKF, and SchulzJB. The mitochondrial chaperone protein TRAP1 mitigates alpha-Synuclein toxicity. PLoS Genet, 8: e1002488, 2012.
63.
ButterfieldDA and KanskiJ. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev, 122: 945–962, 2001.
64.
CairoG, RappoccioloE, TacchiniL, and SchiaffonatiL. Expression of the genes for the ferritin H and L subunits in rat liver and heart. Evidence for tissue-specific regulations at pre- and post-translational levels. Biochem J, 275 (Pt 3): 813–816, 1991.
65.
CalabreseV, MancusoC, RavagnaA, PerluigiM, CiniC, De MarcoC, ButterfieldDA, and StellaAM. In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J Neurochem, 101: 709–717, 2007.
66.
CalabreseV, SultanaR, ScapagniniG, GuaglianoE, SapienzaM, BellaR, KanskiJ, PennisiG, MancusoC, StellaAM, and ButterfieldDA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal, 8: 1975–1986, 2006.
67.
CampanellaA, IsayaG, O'NeillHA, SantambrogioP, CozziA, ArosioP, and LeviS. The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast. Hum Mol Genet, 13: 2279–2288, 2004.
68.
CampanellaA, RovelliE, SantambrogioP, CozziA, TaroniF, and LeviS. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet, 18: 1–11, 2009.
69.
CampuzanoV, MonterminiL, LutzY, CovaL, HindelangC, JiralerspongS, TrottierY, KishSJ, FaucheuxB, TrouillasP, AuthierFJ, DurrA, MandelJL, VescoviA, PandolfoM, and KoenigM. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet, 6: 1771–1780, 1997.
70.
CampuzanoV, MonterminiL, MoltoMD, PianeseL, CosseeM, CavalcantiF, MonrosE, RodiusF, DuclosF, MonticelliA, ZaraF, CanizaresJ, KoutnikovaH, BidichandaniSI, GelleraC, BriceA, TrouillasP, De MicheleG, FillaA, De FrutosR, PalauF, PatelPI, Di DonatoS, MandelJL, CocozzaS, KoenigM, and PandolfoM. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271: 1423–1427, 1996.
71.
CasasC, AldeaM, EspinetC, GallegoC, GilR, and HerreroE. The AFT1 transcriptional factor is differentially required for expression of high-affinity iron uptake genes in Saccharomyces cerevisiae. Yeast, 13: 621–637, 1997.
72.
CaseyJL, HentzeMW, KoellerDM, CaughmanSW, RouaultTA, KlausnerRD, and HarfordJB. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science, 240: 924–928, 1988.
73.
CavadiniP, GelleraC, PatelPI, and IsayaG. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet, 9: 2523–2530, 2000.
74.
CazzolaM, InvernizziR, BergamaschiG, LeviS, CorsiB, TravaglinoE, RolandiV, BiasiottoG, DrysdaleJ, and ArosioP. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood, 101: 1996–2000, 2003.
75.
CeccomJ, CosledanF, HalleyH, FrancesB, LassalleJM, and MeunierB. Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model. PLoS One, 7: e43105, 2012.
76.
CharkoudianLK, DentchevT, LukinovaN, WolkowN, DunaiefJL, and FranzKJ. Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J Inorg Biochem, 102: 2130–2135, 2008.
77.
CharkoudianLK, PhamDM, and FranzKJ. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J Am Chem Soc, 128: 12424–12425, 2006.
78.
ChenH, AttiehZK, SuT, SyedBA, GaoH, AlaeddineRM, FoxTC, UstaJ, NaylorCE, EvansRW, McKieAT, AndersonGJ, and VulpeCD. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood, 103: 3933–3939, 2004.
79.
ChenH, HuangG, SuT, GaoH, AttiehZK, McKieAT, AndersonGJ, and VulpeCD. Decreased hephaestin activity in the intestine of copper-deficient mice causes systemic iron deficiency. J Nutr, 136: 1236–1241, 2006.
80.
ChenW, DaileyHA, and PawBH. Ferrochelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis. Blood, 116: 628–630, 2010.
81.
ChenW, ParadkarPN, LiL, PierceEL, LangerNB, Takahashi-MakiseN, HydeBB, ShirihaiOS, WardDM, KaplanJ, and PawBH. Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci U S A, 106: 16263–16268, 2009.
82.
ChenXZ, PengJB, CohenA, NelsonH, NelsonN, and HedigerMA. Yeast SMF1 mediates H(+)-coupled iron uptake with concomitant uncoupled cation currents. J Biol Chem, 274: 35089–35094, 1999.
83.
ChesebroB, RaceR, and KercherL. Scrapie pathogenesis in brain and retina: effects of prion protein expression in neurons and astrocytes. J Neurovirol, 11: 476–480, 2005.
84.
ChewKC, AngET, TaiYK, TsangF, LoSQ, OngE, OngWY, ShenHM, LimKL, DawsonVL, DawsonTM, and SoongTW. Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease. J Biol Chem, 286: 33380–33389, 2011.
85.
ChoiCJ, AnantharamV, SaetveitNJ, HoukRS, KanthasamyA, and KanthasamyAG. Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death. Toxicol Sci, 98: 495–509, 2007.
86.
ChouAP, LiS, FitzmauriceAG, and BronsteinJM. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology, 31: 367–372, 2010.
87.
ConnorJR, BoeshoreKL, BenkovicSA, and MenziesSL. Isoforms of Ferritin Have a Specific Cellular-Distribution in the Brain. J Neurosci Res, 37: 461–465, 1994.
88.
CookJD, BenczeKZ, JankovicAD, CraterAK, BuschCN, BradleyPB, StemmlerAJ, SpallerMR, and StemmlerTL. Monomeric yeast frataxin is an iron-binding protein. Biochemistry, 45: 7767–7777, 2006.
89.
CoopermanSS, Meyron-HoltzEG, Olivierre-WilsonH, GhoshMC, McConnellJP, and RouaultTA. Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood, 106: 1084–1091, 2005.
90.
CorsiB, CozziA, ArosioP, DrysdaleJ, SantambrogioP, CampanellaA, BiasiottoG, AlbertiniA, and LeviS. Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem, 277: 22430–22437, 2002.
91.
CosseeM, PuccioH, GansmullerA, KoutnikovaH, DierichA, LeMeurM, FischbeckK, DolleP, and KoenigM. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet, 9: 1219–1226, 2000.
92.
CoxTC, BawdenMJ, MartinA, and MayBK. Human erythroid 5-aminolevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. EMBO J, 10: 1891–1902, 1991.
93.
CoxTC, BottomleySS, WileyJS, BawdenMJ, MatthewsCS, and MayBK. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med, 330: 675–679, 1994.
94.
CozziA, SantambrogioP, CorsiB, CampanellaA, ArosioP, and LeviS. Characterization of the L-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder. Neurobiol Dis, 23: 644–652, 2006.
95.
CremonesiL, CozziA, GirelliD, FerrariF, FermoI, FoglieniB, LeviS, BozziniC, CampariniM, FerrariM, and ArosioP. Case report: a subject with a mutation in the ATG start codon of L-ferritin has no haematological or neurological symptoms. J Med Genet, 41: e81, 2004.
96.
CremonesiL, FoglieniB, FermoI, CozziA, ParoniR, RuggeriG, BelloliS, LeviS, FargionS, FerrariM, and ArosioP. Identification of two novel mutations in the 5′ untranslated region of H-ferritin using denaturing high performance liquid chromatography scanning. Haematologica, 88: 1110–1116, 2003.
97.
CrichtonRR, DexterDT, and WardRJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm, 118: 301–314, 2011.
98.
CromptonDE, ChinneryPF, BatesD, WallsTJ, JacksonMJ, CurtisAJ, and BurnJ. Spectrum of movement disorders in neuroferritinopathy. Mov Disord, 20: 95–99, 2005.
99.
CrouchPJ, SavvaMS, HungLW, DonnellyPS, MotAI, ParkerSJ, GreenoughMA, VolitakisI, AdlardPA, ChernyRA, MastersCL, BushAI, BarnhamKJ, and WhiteAR. The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem, 119: 220–230, 2011.
100.
CsereP, LillR, and KispalG. Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p. FEBS Lett, 441: 266–270, 1998.
DaileyHA, SellersVM, and DaileyTA. Mammalian Ferrochelatase—Expression and Characterization of Normal and two Human Protoporhyric Ferrochelatases. J Biol Chem, 269: 390–395, 1994.
103.
DancisA, KlausnerRD, HinnebuschAG, and BarriocanalJG. Genetic evidence that ferric reductase is required for iron uptake in Saccharomyces cerevisiae. Mol Cell Biol, 10: 2294–2301, 1990.
104.
DaviesP, MouallaD, and BrownDR. Alpha-Synuclein Is a Cellular Ferrireductase. PLoS One, 6: e15814, 2011.
105.
DavisBA, O'SullivanC, JarrittPH, and PorterJB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood, 104: 263–269, 2004.
106.
DawsonTM and DawsonVL. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 302: 819–822, 2003.
107.
De DomenicoI, WardDM, Di PattiMCB, JeongSY, DavidS, MusciG, and KaplanJ. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J, 26: 2823–2831, 2007.
108.
De DomenicoI, WardDM, and KaplanJ. Specific iron chelators determine the route of ferritin degradation. Blood, 114: 4546–4551, 2009.
109.
De SilvaDM, AskwithCC, EideD, and KaplanJ. The FET3 gene product required for high affinity iron transport in yeast is a cell surface ferroxidase. J Biol Chem, 270: 1098–1101, 1995.
110.
DeaneR, ZhengW, and ZlokovicBV. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem, 88: 813–820, 2004.
111.
DecressacM, MattssonB, LundbladM, WeikopP, and BjorklundA. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis, 45: 939–953, 2012.
112.
DehayB, BoveJ, Rodriguez-MuelaN, PerierC, RecasensA, BoyaP, and VilaM. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci, 30: 12535–12544, 2010.
113.
DeleaultNR, HarrisBT, ReesJR, and SupattaponeS. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A, 104: 9741–9746, 2007.
114.
DengXL, VidalR, and EnglanderEW. Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett, 479: 44–48, 2010.
115.
DevosD. 2012. Efficacy and safety of the iron chelator deferiprone in Parkinson's disease (FAIR-PARK-I). http://clinicaltrials.gov/ct2/show/NCT00943748?term=iron+chelator+neurodegeneration&rank=1.
116.
DevosD, TchofoPJ, VuillaumeI, DesteeA, BateyS, BurnJ, and ChinneryPF. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain, 132: e109, 2009.
117.
DexterDT, CarayonA, Javoy-AgidF, AgidY, WellsFR, DanielSE, LeesAJ, JennerP, and MarsdenCD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 114 (Pt 4): 1953–1975, 1991.
118.
DexterDT, WellsFR, LeesAJ, AgidF, AgidY, JennerP, and MarsdenCD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem, 52: 1830–1836, 1989.
119.
DezfouliMA, AlaviA, RohaniM, RezvaniM, NekuieT, KlotzleB, TonekaboniSH, ShahidiGA, and ElahiE. PANK2 and C19orf12 mutations are common causes of neurodegeneration with brain iron accumulation. Mov Disord, 28: 228–232, 2013.
120.
Dhe-PaganonS, ShigetaR, ChiYI, RistowM, and ShoelsonSE. Crystal structure of human frataxin. J Biol Chem, 275: 30753–30756, 2000.
121.
Di DomenicoF, BaroneE, MancusoC, PerluigiM, CoccioloA, MecocciP, ButterfieldDA, and CocciaR. HO-1/BVR-A system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease. J Alzheimers Dis, 32: 277–289, 2012.
122.
Di FonzoA, ChienHF, SocalM, GiraudoS, TassorelliC, IlicetoG, FabbriniG, MarconiR, FincatiE, AbbruzzeseG, MariniP, SquitieriF, HorstinkMW, MontagnaP, LiberaAD, StocchiF, GoldwurmS, FerreiraJJ, MecoG, MartignoniE, LopianoL, JardimLB, OostraBA, BarbosaER, and BonifatiV. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 68: 1557–1562, 2007.
123.
DixDR, BridghamJT, BroderiusMA, ByersdorferCA, and EideDJ. The FET4 gene encodes the low affinity Fe(II) transport protein of Saccharomyces cerevisiae. J Biol Chem, 269: 26092–26099, 1994.
124.
DonovanA, LimaCA, PinkusJL, PinkusGS, ZonLI, RobineS, and AndrewsNC. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab, 1: 191–200, 2005.
125.
DrakeSF, MorganEH, HerbisonCE, DelimaR, GrahamRM, ChuaAC, LeedmanPJ, FlemingRE, BaconBR, OlynykJK, and TrinderD. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245×) mutant mouse model of hemochromatosis type 3. Am J Physiol Gastrointest Liver Physiol, 292: G323–G328, 2007.
126.
DrayerB, BurgerP, DarwinR, RiedererS, HerfkensR, and JohnsonGA. MRI of brain iron. AJR Am J Roentgenol, 147: 103–110, 1986.
127.
DrysdaleJ, ArosioP, InvernizziR, CazzolaM, VolzA, CorsiB, BiasiottoG, and LeviS. Mitochondrial ferritin: A new player in iron metabolism. Blood Cells Mol Dis, 29: 376–383, 2002.
128.
DuX, SheE, GelbartT, TruksaJ, LeeP, XiaY, KhovananthK, MuddS, MannN, MorescoEMY, BeutlerE, and BeutlerB. The serine protease TMPRSS6 is required to sense iron deficiency. Science, 320: 1088–1092, 2008.
129.
DuceJA, TsatsanisA, CaterMA, JamesSA, RobbE, WikheK, LeongSL, PerezK, JohanssenT, GreenoughMA, ChoHH, GalatisD, MoirRD, MastersCL, McLeanC, TanziRE, CappaiR, BarnhamKJ, CiccotostoGD, RogersJT, and BushAI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 142: 857–867, 2010.
130.
DuennwaldML, JagadishS, MuchowskiPJ, and LindquistS. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A, 103: 11045–11050, 2006.
131.
DupuyJ, VolbedaA, CarpentierP, DarnaultC, MoulisJM, and Fontecilla-CampsJC. Crystal structure of human iron regulatory protein 1 as cytosolic aconitase. Structure, 14: 129–139, 2006.
132.
DurrA, CosseeM, AgidY, CampuzanoV, MignardC, PenetC, MandelJL, BriceA, and KoenigM. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med, 335: 1169–1175, 1996.
133.
DusekP and SchneiderSA. Neurodegeneration with brain iron accumulation. Curr Opin Neurol, 25: 499–506, 2012.
134.
DwyerBE, NishimuraRN, and LuSY. Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody. Response to oxidative stress. Brain Res Mol Brain Res, 30: 37–47, 1995.
135.
EatonJW and QianM. Molecular bases of cellular iron toxicity. Free Radic Biol Med, 32: 833–840, 2002.
136.
EgashiraY and MatsuyamaH. Subacute myelo-optico-neuropathy (SMON) in Japan. With special reference to the autopsy cases. Acta Pathol Jpn, 32Suppl 1: 101–116, 1982.
137.
EstevesAR, ArduinoDM, SilvaDF, OliveiraCR, and CardosoSM. Mitochondrial dysfunction: the road to alpha-synuclein oligomerization in PD. Park Dis, 2011: 693761, 2011.
138.
Evans-GaleaMV, CorbenLA, HasellJ, GaleaCA, FaheyMC, du SartD, and DelatyckiMB. A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype. Neurogenetics, 12: 307–313, 2011.
139.
FahmyM and YoungSP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J, 296: 175–181, 1993.
140.
FarrerM, StoneJ, MataIF, LincolnS, KachergusJ, HulihanM, StrainKJ, and MaraganoreDM. LRRK2 mutations in Parkinson disease. Neurology, 65: 738–740, 2005.
FearnleyJM and LeesAJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114 (Pt 5): 2283–2301, 1991.
143.
FebbraroF, GiorgiM, CaldarolaS, LoreniF, and Romero-RamosM. alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport, 23: 576–580, 2012.
144.
FernaeusS, HalldinJ, BedecsK, and LandT. Changed iron regulation in scrapie-infected neuroblastoma cells. Brain Res Mol Brain Res, 133: 266–273, 2005.
145.
FernaeusS and LandT. Increased iron-induced oxidative stress and toxicity in scrapie-infected neuroblastoma cells. Neurosci Lett, 382: 217–220, 2005.
146.
Fernandez-BachillerMI, PerezC, Gonzalez-MunozGC, CondeS, LopezMG, VillarroyaM, GarciaAG, and Rodriguez-FrancoMI. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J Med Chem, 53: 4927–4937, 2010.
147.
FerreiraC, BucchiniD, MartinME, LeviS, ArosioP, GrandchampB, and BeaumontC. Early embryonic lethality of H ferritin gene deletion in mice. J Biol Chem, 275: 3021–3024, 2000.
148.
FillaA, DeMicheleG, CavalcantiF, PianeseL, MonticelliA, CampanellaG, and CocozzaS. The relationship between trinucleotide (GAA) repeat length and clinical features in friedreich ataxia. Am J Hum Genet, 59: 554–560, 1996.
149.
FinkAL. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res, 39: 628–634, 2006.
150.
FisherJ, DevrajK, IngramJ, Slagle-WebbB, MadhankumarAB, LiuX, KlingerM, SimpsonIA, and ConnorJR. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol, 293: C641–C649, 2007.
151.
FlemingMD, TrenorCC, SuMA, FoernzlerD, BeierDR, DietrichWF, and AndrewsNC. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet, 16: 383–386, 1997.
152.
FlemingRE, AhmannJR, MigasMC, WaheedA, KoefflerHP, KawabataH, BrittonRS, BaconBR, and SlyWS. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci U S A, 99: 10653–10658, 2002.
153.
FlemingRE, FengQ, and BrittonRS. Knockout mouse models of iron homeostasis. Annu Rev Nutr, 31: 117–137, 2011.
FolkDS and FranzKJ. A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation. J Am Chem Soc, 132: 4994–4995, 2010.
156.
ForniGL. 2012. Ferrochelating treatment in patients affected by neurodegeneration with brain iron accumulation. http://clinicaltrials.gov/ct2/show/NCT00907283?term=iron+chelator+neurodegeneration&rank=2.
157.
FouryF and CazzaliniO. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett, 411: 373–377, 1997.
158.
FouryF and RogantiT. Deletion of the mitochondrial carrier genes MRS3 and MRS4 suppresses mitochondrial iron accumulation in a yeast frataxin-deficient strain. J Biol Chem, 277: 24475–24483, 2002.
159.
FriedlichAL, TanziRE, and RogersJT. The 5′-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry, 12: 222–223, 2007.
160.
FroschauerEM, SchweyenRJ, and WiesenbergerG. The yeast mitochondrial carrier proteins Mrs3p/Mrs4p mediate iron transport across the inner mitochondrial membrane. Biochim Biophys Acta, 1788: 1044–1050, 2009.
161.
GabathulerR. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis, 37: 48–57, 2010.
162.
GaetaA and HiderRC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol, 146: 1041–1059, 2005.
163.
GalyB, FerringD, MinanaB, BellO, JanserHG, MuckenthalerM, SchumannK, and HentzeMW. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood, 106: 2580–2589, 2005.
164.
GaoJW, ChenJX, KramerM, TsukamotoH, ZhangAS, and EnnsCA. Interaction of the Hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab, 9: 217–227, 2009.
165.
GerberJ, MuhlenhoffU, and LillR. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep, 4: 906–911, 2003.
166.
GibsonTJ, KooninEV, MuscoG, PastoreA, and BorkP. Friedreich's ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci, 19: 465–468, 1996.
167.
GieseA and KretzschmarHA. Prion-induced neuronal damage—the mechanisms of neuronal destruction in the subacute spongiform encephalopathies. Curr Top Microbiol Immunol, 253: 203–217, 2001.
168.
GirelliD, CorrocherR, BiscegliaL, OlivieriO, De FranceschiL, ZelanteL, and GaspariniP. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the “Verona mutation”). Blood, 86: 4050–4053, 1995.
169.
GitlerAD, ChesiA, GeddieML, StrathearnKE, HamamichiS, HillKJ, CaldwellKA, CaldwellGA, CooperAA, RochetJC, and LindquistS. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet, 41: 308–315, 2009.
170.
GongHS, GuoY, TianC, XieWL, ShiQ, ZhangJ, XuY, WangSB, ZhangBY, ChenC, LiuY, and DongXP. Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrPSc. Int J Mol Med, 30: 569–578, 2012.
171.
GoralskaM, HolleyBL, and McGahanMC. Overexpression of H- and L-ferritin subunits in lens epithelial cells: Fe metabolism and cellular response to UVB irradiation. Invest Ophthalmol Vis Sci, 42: 1721–1727, 2001.
172.
GotzME, DoubleK, GerlachM, YoudimMB, and RiedererP. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci, 1012: 193–208, 2004.
173.
GranzottoA and ZattaP. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Abeta and Abeta-metal complexes toxicity. PLoS One, 6: e21565, 2011.
174.
GregoryA, PolsterBJ, and HayflickSJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet, 46: 73–80, 2009.
GriffioenG, DuhamelH, Van DammeN, PellensK, ZabrockiP, PannecouqueC, van LeuvenF, WinderickxJ, and WeraS. A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta, 1762: 312–318, 2006.
177.
GriffithsPD and CrossmanAR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia, 4: 61–65, 1993.
178.
GuerreiroRJ, BrasJM, SantanaI, JanuarioC, SantiagoB, MorgadinhoAS, RibeiroMH, HardyJ, SingletonA, and OliveiraC. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol, 6: 24, 2006.
179.
GuldenerU, MunsterkotterM, KastenmullerG, StrackN, van HeldenJ, LemerC, RichellesJ, WodakSJ, Garcia-MartinezJ, Perez-OrtinJE, MichaelH, KapsA, TallaE, DujonB, AndreB, SoucietJL, De MontignyJ, BonE, GaillardinC, and MewesHW. CYGD: the Comprehensive Yeast Genome Database. Nucleic Acids Res, 33: D364–D368, 2005.
180.
GunshinH, AllersonCR, Polycarpou-SchwarzM, RoftsA, RogersJT, KishiF, HentzeMW, RouaultTA, AndrewsNC, and HedigerMA. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett, 509: 309–316, 2001.
181.
GuoC, WangT, ZhengW, ShanZY, TengWP, and WangZY. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging, 34: 562–575, 2013.
182.
GutteridgeJM, RowleyDA, and HalliwellB. Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of ‘catalytic’ iron and anti-oxidant activity in extracellular fluids. Biochem J, 206: 605–609, 1982.
183.
HaackeEM, ChengNY, HouseMJ, LiuQ, NeelavalliJ, OggRJ, KhanA, AyazM, KirschW, and ObenausA. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging, 23: 1–25, 2005.
184.
HaassC and SelkoeDJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol, 8: 101–112, 2007.
185.
HaldarS, BeveridgeAJ, WongJ, SinghA, GalimbertiD, BorroniB, ZhuX, BlevinsJ, GreenleeJJ, PerryG, MukhopadhyayC, SchmotzerC, and SinghN. A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. Antioxid Redox Signal, 19: 1662–1675, 2013.
186.
HalliwellB and GutteridgeJMC. Biologically Relevant Metal Ion-Dependent Hydroxyl Radical Generation—an Update. FEBS Lett, 307: 108–112, 1992.
187.
HardingAE. “Idiopathic” late onset cerebellar ataxia. A clinical and genetic study of 36 cases. J Neurol Sci, 51: 259–271, 1981.
188.
HardyJ. Genetic analysis of pathways to Parkinson disease. Neuron, 68: 201–206, 2010.
189.
HarrisZL, DurleyAP, ManTK, and GitlinJD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci U S A, 96: 10812–10817, 1999.
190.
HarrisZL, TakahashiY, MiyajimaH, SerizawaM, MacGillivrayRT, and GitlinJD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A, 92: 2539–2543, 1995.
191.
HartigMB, HortnagelK, GaravagliaB, ZorziG, KmiecT, KlopstockT, RostasyK, SvetelM, KosticVS, SchuelkeM, BotzE, WeindlA, NovakovicI, NardocciN, ProkischH, and MeitingerT. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol, 59: 248–256, 2006.
192.
HartigMB, IusoA, HaackT, KmiecT, JurkiewiczE, HeimK, RoeberS, TarabinV, DusiS, Krajewska-WalasekM, JozwiakS, HempelM, WinkelmannJ, ElstnerM, OexleK, KlopstockT, Mueller-FelberW, GasserT, TrenkwalderC, TirantiV, KretzschmarH, SchmitzG, StromTM, MeitingerT, and ProkischH. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet, 89: 543–550, 2011.
193.
HauserDN and HastingsTG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis: 35–42, 2013.
194.
HayflickSJ, WestawaySK, LevinsonB, ZhouB, JohnsonMA, ChingKH, and GitschierJ. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med, 348: 33–40, 2003.
195.
HeY, AlamSL, ProteasaSV, ZhangY, LesuisseE, DancisA, and StemmlerTL. Yeast frataxin solution structure, iron binding, and ferrochelatase interaction. Biochemistry, 43: 16254–16262, 2004.
196.
HentzeMW and KuhnLC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A, 93: 8175–8182, 1996.
197.
HentzeMW, MuckenthalerMU, GalyB, and CamaschellaC. Two to tango: regulation of Mammalian iron metabolism. Cell, 142: 24–38, 2010.
198.
HeskethS, SassoonJ, KnightR, and BrownDR. Elevated manganese levels in blood and CNS in human prion disease. Mol Cell Neurosci, 37: 590–598, 2008.
199.
HidaA, KowaH, IwataA, TanakaM, KwakS, and TsujiS. Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis. J Neurol Sci, 298: 136–139, 2010.
200.
HintzeKJ and TheilEC. DNA and mRNA elements with complementary responses to hemin, antioxidant inducers, and iron control ferritin-L expression. Proc Natl Acad Sci U S A, 102: 15048–15052, 2005.
201.
HochstrasserH, TomiukJ, WalterU, BehnkeS, SpiegelJ, KrugerR, BeckerG, RiessO, and BergD. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J, 19: 1851–1853, 2005.
202.
HuangML, BeckerEM, WhitnallM, Suryo RahmantoY, PonkaP, and RichardsonDR. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A, 106: 16381–16386, 2009.
203.
HuangXD, AtwoodCS, MoirRD, HartshornMA, TanziRE, and BushAI. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's A beta peptides. J Biol Inorg Chem, 9: 954–960, 2004.
204.
HughesAJ, DanielSE, KilfordL, and LeesAJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55: 181–184, 1992.
205.
HuiY, WangD, LiW, ZhangL, JinJ, MaN, ZhouL, NakajimaO, ZhaoW, and GaoX. Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. J Alzheimers Dis, 26: 299–313, 2011.
206.
HunotS and HirschEC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol, 53Suppl 3: S49–S58; discussion S58–S60, 2003.
207.
HurK, KimJI, ChoiSI, ChoiEK, CarpRI, and KimYS. The pathogenic mechanisms of prion diseases. Mech Ageing Dev, 123: 1637–1647, 2002.
208.
HwangD, LeeIY, YooH, GehlenborgN, ChoJH, PetritisB, BaxterD, PitstickR, YoungR, SpicerD, PriceND, HohmannJG, DeArmondSJ, CarlsonGA, and HoodLE. A systems approach to prion disease. Mol Syst Biol, 5: 252, 2009.
209.
JeongSY, CrooksDR, Wilson-OllivierreH, GhoshMC, SougratR, LeeJ, CoopermanS, MitchellJB, BeaumontC, and RouaultTA. Iron insufficiency compromises motor neurons and their mitochondrial function in Irp2-null mice. PLoS One, 6: e25404, 2011.
210.
JeongSY and DavidS. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem, 278: 27144–27148, 2003.
211.
JeongSY and DavidS. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci, 26: 9810–9819, 2006.
212.
JiaoY, WilkinsonJt, DiX, WangW, HatcherH, KockND, D'AgostinoRJr., KnovichMA, TortiFM, and TortiSV. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood, 113: 462–469, 2009.
213.
JohanssonC, RoosAK, MontanoSJ, SenguptaR, FilippakopoulosP, GuoK, von DelftF, HolmgrenA, OppermannU, and KavanaghKL. The crystal structure of human GLRX5: iron-sulfur cluster co-ordination, tetrameric assembly and monomer activity. Biochem J, 433: 303–311, 2011.
214.
JonesCE, AbdelraheimSR, BrownDR, and VilesJH. Preferential Cu2+ coordination by His96 and His111 induces beta-sheet formation in the unstructured amyloidogenic region of the prion protein. J Biol Chem, 279: 32018–32027, 2004.
215.
JonesCE, KlewpatinondM, AbdelraheimSR, BrownDR, and VilesJH. Probing copper2+ binding to the prion protein using diamagnetic nickel2+ and 1H NMR: the unstructured N terminus facilitates the coordination of six copper2+ ions at physiological concentrations. J Mol Biol, 346: 1393–1407, 2005.
216.
JoshiJG, FlemingJT, DharM, and ChauthaiwaleV. A novel ferritin heavy chain messenger ribonucleic acid in the human brain. J Neurol Sci, 134: 52–56, 1995.
217.
KannengiesserC, JouanolleAM, HetetG, MosserA, MuzeauF, HenryD, Bardou-JacquetE, MornetM, BrissotP, DeugnierY, GrandchampB, and BeaumontC. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica, 94: 335–339, 2009.
218.
KaplanJ, WardDM, and De DomenicoI. The molecular basis of iron overload disorders and iron-linked anemias. Int J Hematol, 93: 14–20, 2011.
219.
KatoJ, FujikawaK, KandaM, FukudaN, SasakiK, TakayamaT, KobuneM, TakadaK, TakimotoR, HamadaH, IkedaT, and NiitsuY. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet, 69: 191–197, 2001.
220.
KaurD, PengJ, ChintaSJ, RajagopalanS, Di MonteDA, ChernyRA, and AndersenJK. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging, 28: 907–913, 2007.
221.
KaurD, YantiriF, RajagopalanS, KumarJ, MoJQ, BoonplueangR, ViswanathV, JacobsR, YangL, BealMF, DiMonteD, VolitaskisI, EllerbyL, ChernyRA, BushAI, and AndersenJK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron, 37: 899–909, 2003.
222.
KawabataH, FlemingRE, GuiD, MoonSY, SaitohT, O'KellyJ, UmeharaY, WanoY, SaidJW, and KoefflerHP. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood, 105: 376–381, 2005.
223.
KawabataH, YangR, HiramaT, VuongPT, KawanoS, GombartAF, and KoefflerHP. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem, 274: 20826–20832, 1999.
224.
KeY and QianZM. Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol, 83: 149–173, 2007.
225.
KellD. Journal club. A systems biologist ponders how disparate ideas can sometimes come together beautifully. Nature, 460: 669, 2009.
226.
KellDB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol, 84: 825–889, 2010.
227.
KidaneTZ, SaubleE, and LinderMC. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol, 291: C445–C455, 2006.
228.
KielarF, HelselME, WangQ, and FranzKJ. Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics, 4: 899–909, 2012.
229.
KikuchiG, YoshidaT, and NoguchiM. Heme oxygenase and heme degradation. Biochem Biophys Res Commun, 338: 558–567, 2005.
230.
KimNH, ParkSJ, JinJK, KwonMS, ChoiEK, CarpRI, and KimYS. Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice. Brain Res, 884: 98–103, 2000.
231.
KispalG, CsereP, GuiardB, and LillR. The ABC transporter Atm1p is required for mitochondrial iron homeostasis. FEBS Lett, 418: 346–350, 1997.
232.
KispalG, CsereP, ProhlC, and LillR. The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J, 18: 3981–3989, 1999.
233.
KitadaT, AsakawaS, HattoriN, MatsumineH, YamamuraY, MinoshimaS, YokochiM, MizunoY, and ShimizuN. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392: 605–608, 1998.
234.
KlamtF, Dal-PizzolF, Conte da FrotaMLJr., WalzR, AndradesME, da SilvaEG, BrentaniRR, IzquierdoI, and Fonseca MoreiraJC. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol Med, 30: 1137–1144, 2001.
235.
KlompLW, FarhangraziZS, DuganLL, and GitlinJD. Ceruloplasmin gene expression in the murine central nervous system. J Clin Invest, 98: 207–215, 1996.
236.
KlompLW and GitlinJD. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet, 5: 1989–1996, 1996.
237.
KoeppenAH, MichaelSC, KnutsonMD, HaileDJ, QianJ, LeviS, SantambrogioP, GarrickMD, and LamarcheJB. The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol, 114: 163–173, 2007.
238.
KoeppenAH, MorralJA, DavisAN, QianJ, PetrocineSV, KnutsonMD, GibsonWM, CusackMJ, and LiD. The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol, 118: 763–776, 2009.
239.
KotzbauerPT, TruaxAC, TrojanowskiJQ, and LeeVM. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci, 25: 689–698, 2005.
240.
KoutnikovaH, CampuzanoV, FouryF, DolleP, CazzaliniO, and KoenigM. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet, 16: 345–351, 1997.
241.
KramerMF, GunaratneP, and FerreiraGC. Transcriptional regulation of the murine erythroid-specific 5-aminolevulinate synthase gene. Gene, 247: 153–166, 2000.
242.
KrishnamurthiRV, MathaiS, KimAH, ZhangR, and GuanJ. A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats. Br J Pharmacol, 156: 662–672, 2009.
243.
KruerMC, BoddaertN, SchneiderSA, HouldenH, BhatiaKP, GregoryA, AndersonJC, RooneyWD, HogarthP, and HayflickSJ. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol, 33: 407–414, 2012.
244.
KruerMC, Paisan-RuizC, BoddaertN, YoonMY, HamaH, GregoryA, MalandriniA, WoltjerRL, MunnichA, GobinS, PolsterBJ, PalmeriS, EdvardsonS, HardyJ, HouldenH, and HayflickSJ. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol, 68: 611–618, 2010.
245.
KruerMC, PaudelR, WagonerW, SanfordL, KaraE, GregoryA, FoltynieT, LeesA, BhatiaK, HardyJ, HayflickSJ, and HouldenH. Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts. Neurosci Lett, 523: 35–38, 2012.
246.
KubotaA, HidaA, IchikawaY, MomoseY, GotoJ, IgetaY, HashidaH, YoshidaK, IkedaS, KanazawaI, and TsujiS. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov Disord, 24: 441–445, 2009.
247.
KupershmidtL, WeinrebO, AmitT, MandelS, Bar-AmO, and YoudimMB. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience, 189: 345–358, 2011.
248.
KurianMA, McNeillA, LinJP, and MaherER. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol, 53: 394–404, 2011.
249.
KuriyamaS, ShimazuT, OhmoriK, KikuchiN, NakayaN, NishinoY, TsubonoY, and TsujiI. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. J Am Med Assoc, 296: 1255–1265, 2006.
250.
KurtzJE, DufourP, DuclosB, BergeratJP, and ExingerF. [Saccharomyces cerevisiae: an efficient tool and model system for anticancer research]. Bull Cancer, 91: 133–139, 2004.
251.
LabunskyyVM and GladyshevVN. Role of reactive oxygen species-mediated signaling in aging. Antioxid Redox Signal, 19: 1362–1372, 2013.
252.
LandT and RouaultTA. Targeting of a human iron-sulfur cluster assembly enzyme, nifs, to different subcellular compartments is regulated through alternative AUG utilization. Mol Cell, 2: 807–815, 1998.
253.
LaneDJ, RobinsonSR, CzerwinskaH, BishopGM, and LawenA. Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron. Biochem J, 432: 123–132, 2010.
254.
LangAE and LozanoAM. Parkinson's disease. Second of two parts. N Engl J Med, 339: 1130–1143, 1998.
255.
LaVauteT, SmithS, CoopermanS, IwaiK, LandW, Meyron-HoltzE, DrakeSK, MillerG, Abu-AsabM, TsokosM, SwitzerR3rd, GrinbergA, LoveP, TresserN, and RouaultTA. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet, 27: 209–214, 2001.
256.
LayerG, Ollagnier-de ChoudensS, SanakisY, and FontecaveM. Iron-sulfur cluster biosynthesis: characterization of Escherichia coli CYaY as an iron donor for the assembly of [2Fe-2S] clusters in the scaffold IscU. J Biol Chem, 281: 16256–16263, 2006.
257.
LazarouM, NarendraDP, JinSM, TekleE, BanerjeeS, and YouleRJ. PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol, 200: 163–172, 2013.
258.
LeggettBA, FletcherLM, RammGA, PowellLW, and HallidayJW. Differential regulation of ferritin H and L subunit mRNA during inflammation and long-term iron overload. J Gastroenterol Hepatol, 8: 21–27, 1993.
259.
LeiP, AytonS, FinkelsteinDI, SpoerriL, CiccotostoGD, WrightDK, WongBX, AdlardPA, ChernyRA, LamLQ, RobertsBR, VolitakisI, EganGF, McLeanCA, CappaiR, DuceJA, and BushAI. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med, 18: 291–295, 2012.
260.
LeidgensS, De SmetS, and FouryF. Frataxin interacts with Isu1 through a conserved tryptophan in its beta-sheet. Hum Mol Genet, 19: 276–286, 2010.
261.
Lesbordes-BrionJC, ViatteL, BennounM, LouDQ, RameyG, HoubronC, HamardG, KahnA, and VaulontS. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood, 108: 1402–1405, 2006.
262.
LeviS, CorsiB, BosisioM, InvernizziR, VolzA, SanfordD, ArosioP, and DrysdaleJ. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem, 276: 24437–24440, 2001.
263.
LeviS and RovidaE. The role of iron in mitochondrial function. Biochim Biophys Acta, 1790: 629–636, 2009.
264.
LevyJE, JinO, FujiwaraY, KuoF, and AndrewsNC. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet, 21: 396–399, 1999.
265.
LiA, DongJ, and HarrisDA. Cell surface expression of the prion protein in yeast does not alter copper utilization phenotypes. J Biol Chem, 279: 29469–29477, 2004.
266.
LiK, BesseEK, HaD, KovtunovychG, and RouaultTA. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet, 17: 2265–2273, 2008.
267.
LiY, TianX, QianL, YuX, and JiangW. Anodal transcranial direct current stimulation relieves the unilateral bias of a rat model of Parkinson's disease. Conf Proc IEEE Eng Med Biol Soc, 2011: 765–768, 2011.
268.
LimCK, KalinowskiDS, and RichardsonDR. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Mol Pharmacol, 74: 225–235, 2008.
269.
LimJE, JinO, BennettC, MorganK, WangF, TrenorCC3rd, FlemingMD, and AndrewsNC. A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet, 37: 1270–1273, 2005.
270.
LimSK, KimH, bin AliA, LimYK, WangY, ChongSM, CostantiniF, and BaummanH. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood, 92: 1870–1877, 1998.
271.
LinAM, YangCH, and ChaiCY. Striatal dopamine dynamics are altered following an intranigral infusion of iron in adult rats. Free Radic Biol Med, 24: 988–993, 1998.
272.
LiochevSI and FridovichI. The role of O2.- in the production of HO.: in vitro and in vivo. Free Radic Biol Med, 16: 29–33, 1994.
273.
LiuX, JinW, and TheilEC. Opening protein pores with chaotropes enhances Fe reduction and chelation of Fe from the ferritin biomineral. Proc Natl Acad Sci U S A, 100: 3653–3658, 2003.
274.
LiuXS, PattersonLD, MillerMJ, and TheilEC. Peptides selected for the protein nanocage pores change the rate of iron recovery from the ferritin mineral. J Biol Chem, 282: 31821–31825, 2007.
275.
LiuzziJP, AydemirF, NamH, KnutsonMD, and CousinsRJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci U S A, 103: 13612–13617, 2006.
276.
LothariusJ and BrundinP. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci, 3: 932–942, 2002.
277.
LovellMA, RobertsonJD, TeesdaleWJ, CampbellJL, and MarkesberyWR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci, 158: 47–52, 1998.
278.
LvZ, JiangH, XuH, SongN, and XieJ. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm, 118: 361–369, 2011.
279.
LyoumiS, AbitbolM, AndrieuV, HeninD, RobertE, SchmittC, GouyaL, de VerneuilH, DeybachJC, MontagutelliX, BeaumontC, and PuyH. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood, 109: 811–818, 2007.
MacKenzieEL, IwasakiK, and TsujiY. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal, 10: 997–1030, 2008.
282.
MackovaE, HruskovaK, BendovaP, VavrovaA, JansovaH, HaskovaP, KovarikovaP, VavrovaK, and SimunekT. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action. Chem Biol Interact, 197: 69–79, 2012.
283.
MadsenE and GitlinJD. Copper and iron disorders of the brain. Annu Rev Neurosci, 30: 317–337, 2007.
284.
MagnessST, MaedaN, and BrennerDA. An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria. Blood, 100: 1470–1477, 2002.
MaleckiEA, DevenyiAG, BeardJL, and ConnorJR. Existing and emerging mechanisms for transport of iron and manganese to the brain. J Neurosci Res, 56: 113–122, 1999.
287.
MalikI, TurkJ, MancusoDJ, MontierL, WohltmannM, WozniakDF, SchmidtRE, GrossRW, and KotzbauerPT. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol, 172: 406–416, 2008.
288.
MallucciGR, WhiteMD, FarmerM, DickinsonA, KhatunH, PowellAD, BrandnerS, JefferysJG, and CollingeJ. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron, 53: 325–335, 2007.
289.
MancusoC and BaroneE. Curcumin in clinical practice: myth or reality?. Trends Pharmacol Sci, 30: 333–334, 2009.
290.
MancusoC and BaroneE. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr Drug Metab, 10: 579–594, 2009.
291.
MancusoC, SicilianoR, and BaroneE. Curcumin and Alzheimer disease: this marriage is not to be performed. J Biol Chem, 286: le3; author reply le4, 2011.
292.
MancusoM, DavidzonG, KurlanRM, TawilR, BonillaE, Di MauroS, and PowersJM. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol, 64: 280–294, 2005.
293.
MarroS, BarisaniD, ChiabrandoD, FagooneeS, MuckenthalerMU, StolteJ, MeneveriR, HaileD, SilengoL, AltrudaF, and TolosanoE. Lack of haptoglobin affects iron transport across duodenum by modulating ferroportin expression. Gastroenterology, 133: 1261–1271, 2007.
MasisonDC and WicknerRB. Prion-inducing domain of yeast Ure2p and protease resistance of Ure2p in prion-containing cells. Science, 270: 93–95, 1995.
298.
MastroberardinoPG, HoffmanEK, HorowitzMP, BetarbetR, TaylorG, ChengD, NaHM, GutekunstCA, GearingM, TrojanowskiJQ, AndersonM, ChuCT, PengJ, and GreenamyreJT. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis, 34: 417–431, 2009.
299.
McKieAT, MarcianiP, RolfsA, BrennanK, WehrK, BarrowD, MiretS, BomfordA, PetersTJ, FarzanehF, HedigerMA, HentzeMW, and SimpsonRJ. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell, 5: 299–309, 2000.
300.
McLachlanDR, SmithWL, and KruckTP. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther Drug Monit, 15: 602–607, 1993.
301.
MenaNP, BulteauAL, SalazarJ, HirschEC, and NunezMT. Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity. Biochem Biophys Res Commun, 409: 241–246, 2011.
302.
MeriinAB, ZhangX, HeX, NewnamGP, ChernoffYO, and ShermanMY. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol, 157: 997–1004, 2002.
303.
MessaE, PellegrinoRM, PalmieriA, CarturanS, CilloniD, SaglioG, and RoettoA. Identification of a novel mutation in the L ferritin iron-responsive element causing hereditary hyperferritinemia-cataract syndrome. Acta Haematol, 122: 223–225, 2009.
304.
MeynardD, KautzL, DarnaudV, Canonne-HergauxF, CoppinH, and RothMP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet, 41: 478–481, 2009.
305.
Miller-FlemingL, GiorginiF, and OuteiroTF. Yeast as a model for studying human neurodegenerative disorders. Biotechnol J, 3: 325–338, 2008.
306.
MillerLL, MillerSC, TortiSV, TsujiY, and TortiFM. Iron-Independent Induction of Ferritin-H Chain by Tumor-Necrosis-Factor. Proc Natl Acad Sci U S A, 88: 4946–4950, 1991.
307.
MiuraT, SasakiS, ToyamaA, and TakeuchiH. Copper reduction by the octapeptide repeat region of prion protein: pH dependence and implications in cellular copper uptake. Biochemistry, 44: 8712–8720, 2005.
308.
MiyajimaH. Aceruloplasminemia, an iron metabolic disorder. Neuropathology, 23: 345–350, 2003.
309.
MiyajimaH, NishimuraY, MizoguchiK, SakamotoM, ShimizuT, and HondaN. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology, 37: 761–767, 1987.
310.
MooreDJ, WestAB, DawsonVL, and DawsonTM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci, 28: 57–87, 2005.
311.
MoosT. Brain iron homeostasis. Dan Med Bull, 49: 279–301, 2002.
312.
MoosT, Rosengren NielsenT, SkjorringeT, and MorganEH. Iron trafficking inside the brain. J Neurochem, 103: 1730–1740, 2007.
313.
MuckenthalerMU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab, 8: 1–3, 2008.
314.
MuhlenhoffU, RichhardtN, RistowM, KispalG, and LillR. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet, 11: 2025–2036, 2002.
315.
MuhlenhoffU, StadlerJA, RichhardtN, SeubertA, EickhorstT, SchweyenRJ, LillR, and WiesenbergerG. A specific role of the yeast mitochondrial carriers Mrs3/4p in mitochondrial iron acquisition under iron-limiting conditions. J Biol Chem, 278: 40612–40620, 2003.
316.
MuhoberacBB, BaraibarMA, and VidalR. Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that. BBA Mol Basis Dis, 1812: 544–548, 2011.
317.
MumfordAD, CreeIA, ArnoldJD, HaganMC, RixonKC, and HardingJJ. The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritin. Br J Ophthalmol, 84: 697–700, 2000.
318.
MuscoG, StierG, KolmererB, AdinolfiS, MartinS, FrenkielT, GibsonT, and PastoreA. Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin. Structure, 8: 695–707, 2000.
319.
NapierI, PonkaP, and RichardsonDR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood, 105: 1867–1874, 2005.
320.
NemethE, TuttleMS, PowelsonJ, VaughnMB, DonovanA, WardDM, GanzT, and KaplanJ. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306: 2090–2093, 2004.
321.
NicolasG, BennounM, DevauxI, BeaumontC, GrandchampB, KahnA, and VaulontS. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A, 98: 8780–8785, 2001.
322.
NieGJ, SheftelAD, KimSF, and PonkaP. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood, 105: 2161–2167, 2005.
323.
NuttJG and WootenGF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med, 353: 1021–1027, 2005.
324.
NuytemansK, TheunsJ, CrutsM, and Van BroeckhovenC. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat, 31: 763–780, 2010.
325.
OakleyAE, CollingwoodJF, DobsonJ, LoveG, PerrottHR, EdwardsonJA, ElstnerM, and MorrisCM. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology, 68: 1820–1825, 2007.
326.
OexleH, GnaigerE, and WeissG. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta, 1413: 99–107, 1999.
327.
OhgamiRS, CampagnaDR, GreerEL, AntiochosB, McDonaldA, ChenJ, SharpJJ, FujiwaraY, BarkerJE, and FlemingMD. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet, 37: 1264–1269, 2005.
328.
OhshimaK, MonterminiL, WellsRD, and PandolfoM. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem, 273: 14588–14595, 1998.
329.
OhtaE, NagasakaT, ShindoK, TomaS, NagasakaK, OhtaK, and ShiozawaZ. Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology, 70: 1493–1494, 2008.
330.
OlivieriS, ContiA, IannacconeS, CannistraciCV, CampanellaA, BarbarigaM, CodazziF, PelizzoniI, MagnaniG, PescaM, FranciottaD, CappaSF, and AlessioM. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci, 31: 18568–18577, 2011.
331.
OsakiS and JohnsonDA. Mobilization of Liver Iron by Ferroxidase (Ceruloplasmin). J Biol Chem, 244: 5757–5758, 1969.
332.
Ostrerova-GoltsN, PetrucelliL, HardyJ, LeeJM, FarerM, and WolozinB. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci, 20: 6048–6054, 2000.
333.
OuteiroTF and LindquistS. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science, 302: 1772–1775, 2003.
334.
PagonRA, BirdTD, DetterJC, and PierceI. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet, 22: 267–273, 1985.
335.
Paisan-RuizC, LiA, SchneiderSA, HoltonJL, JohnsonR, KiddD, ChatawayJ, BhatiaKP, LeesAJ, HardyJ, ReveszT, and HouldenH. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging, 33: 814–823, 2012.
336.
PandeyA, YoonH, LyverER, DancisA, and PainD. Isd11p protein activates the mitochondrial cysteine desulfurase Nfs1p protein. J Biol Chem, 286: 38242–38252, 2011.
ParadkarPN, ZumbrennenKB, PawBH, WardDM, and KaplanJ. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol Cell Biol, 29: 1007–1016, 2009.
339.
ParkS, GakhO, O'NeillHA, MangravitaA, NicholH, FerreiraGC, and IsayaG. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem, 278: 31340–31351, 2003.
340.
PatelBN, DunnRJ, and DavidS. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem, 275: 4305–4310, 2000.
341.
PatelBN, DunnRJ, JeongSY, ZhuQ, JulienJP, and DavidS. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci, 22: 6578–6586, 2002.
342.
PaulyPC and HarrisDA. Copper stimulates endocytosis of the prion protein. J Biol Chem, 273: 33107–33110, 1998.
343.
PengJ, PengL, StevensonFF, DoctrowSR, and AndersenJK. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J Neurosci, 27: 6914–6922, 2007.
344.
PerezCA, TongY, and GuoM. Iron chelators as potential therapeutic agents for Parkinson's disease. Curr Bioact Compd, 4: 150–158, 2008.
345.
PetersenRB, SiedlakSL, LeeHG, KimYS, NunomuraA, TagliaviniF, GhettiB, CrasP, MoreiraPI, CastellaniRJ, GuentchevM, BudkaH, IronsideJW, GambettiP, SmithMA, and PerryG. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol, 110: 232–238, 2005.
346.
PicardV, EpsztejnS, SantambrogioP, CabantchikZI, and BeaumontC. Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J Biol Chem, 273: 15382–15386, 1998.
347.
PierreJL, BaretP, and SerratriceG. Hydroxyquinolines as iron chelators. Curr Med Chem, 10: 1077–1084, 2003.
348.
PietschEC, ChanJY, TortiFM, and TortiSV. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem, 278: 2361–2369, 2003.
349.
PilslA and WinklhoferKF. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol, 123: 173–188, 2012.
350.
PoliM, DerosasM, LuscietiS, CavadiniP, CampanellaA, VerardiR, FinazziD, and ArosioP. Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction, cell-specific ferroportin upregulation and iron deregulation. Neurobiol Dis, 39: 204–210, 2010.
351.
PollakY, MechlovichD, AmitT, Bar-AmO, ManovI, MandelSA, WeinrebO, Meyron-HoltzEG, IancuTC, and YoudimMB. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. J Neural Transm, 120: 37–48, 2013.
352.
PolymeropoulosMH, LavedanC, LeroyE, IdeSE, DehejiaA, DutraA, PikeB, RootH, RubensteinJ, BoyerR, StenroosES, ChandrasekharappaS, AthanassiadouA, PapapetropoulosT, JohnsonWG, LazzariniAM, DuvoisinRC, Di IorioG, GolbeLI, and NussbaumRL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276: 2045–2047, 1997.
353.
PondarreC, AntiochosBB, CampagnaDR, GreerEL, DeckKM, McDonaldA, HanAP, MedlockA, KutokJL, AndersonSA, EisensteinRS, and FlemingMD. The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. Hum Mol Genet, 15: 953–964, 2006.
354.
PossKD and TonegawaS. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci U S A, 94: 10919–10924, 1997.
355.
PowersJM. p53-mediated apoptosis, neuroglobin overexpression, and globin deposits in a patient with hereditary ferritinopathy. J Neuropathol Exp Neurol, 65: 716–721, 2006.
356.
PrasanthiJR, SchragM, DasariB, MarwarhaG, DicksonA, KirschWM, and GhribiO. Deferiprone reduces amyloid-beta and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis, 30: 167–182, 2012.
357.
PrimosighJV and ThomasED. Studies on the partition of iron in bone marrow cells. J Clin Invest, 47: 1473–1482, 1968.
358.
PrischiF, KonarevPV, IannuzziC, PastoreC, AdinolfiS, MartinSR, SvergunDI, and PastoreA. Structural bases for the interaction of frataxin with the central components of iron-sulphur cluster assembly. Nat Commun, 1: 95, 2010.
359.
PrusinerSB. The prion diseases. Brain Pathol, 8: 499–513, 1998.
360.
PrusinerSB. Prions. Proc Natl Acad Sci U S A, 95: 13363–13383, 1998.
361.
PuccioH, SimonD, CosseeM, Criqui-FilipeP, TizianoF, MelkiJ, HindelangC, MatyasR, RustinP, and KoenigM. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet, 27: 181–186, 2001.
362.
RadfordHE and MallucciGR. The role of GPI-anchored PrP C in mediating the neurotoxic effect of scrapie prions in neurons. Curr Issues Mol Biol, 12: 119–127, 2010.
363.
RadiskyDC, BabcockMC, and KaplanJ. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem, 274: 4497–4499, 1999.
364.
RamazzottiA, VanmansartV, and FouryF. Mitochondrial functional interactions between frataxin and Isu1p, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae. FEBS Lett, 557: 215–220, 2004.
365.
RamirezA, HeimbachA, GrundemannJ, StillerB, HampshireD, CidLP, GoebelI, MubaidinAF, WriekatAL, RoeperJ, Al-DinA, HillmerAM, KarsakM, LissB, WoodsCG, BehrensMI, and KubischC. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet, 38: 1184–1191, 2006.
366.
ReligaD, StrozykD, ChernyRA, VolitakisI, HaroutunianV, WinbladB, NaslundJ, and BushAI. Elevated cortical zinc in Alzheimer disease. Neurology, 67: 69–75, 2006.
367.
RhodesSL and RitzB. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis, 32: 183–195, 2008.
368.
RichardsonDR, LaneDJR, BeckerEM, HuangMLH, WhitnallM, RahmantoYS, SheftelAD, and PonkaP. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A, 107: 10775–10782, 2010.
369.
RichardsonDR, PonkaP, and VyoralD. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood, 87: 3477–3488, 1996.
370.
RistowM, MulderH, PomplunD, SchulzT, Muller-SchmehlK, KrauseA, FexM, PuccioH, MullerJ, IskenF, SprangerJ, Muller-WielandD, MagnusonMA, MohligM, KoenigM, and PfeifferAFH. Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest, 112: 527–534, 2003.
371.
RitchieCW, BushAI, MackinnonA, MacfarlaneS, MastwykM, MacGregorL, KiersL, ChernyR, LiQX, TammerA, CarringtonD, MavrosC, VolitakisI, XilinasM, AmesD, DavisS, BeyreutherK, TanziRE, and MastersCL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60: 1685–1691, 2003.
372.
RogersJT, BushAI, ChoHH, SmithDH, ThomsonAM, FriedlichAL, LahiriDK, LeedmanPJ, HuangXD, and CahillCM. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans, 36: 1282–1287, 2008.
373.
RogersJT, RandallJD, CahillCM, EderPS, HuangXD, GunshinH, LeiterL, McPheeJ, SarangSS, UtsukiT, GreigNH, LahiriDK, TanziRE, BushAI, GiordanoT, and GullansSR. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem, 277: 45518–45528, 2002.
374.
RothJA, SingletonS, FengJ, GarrickM, and ParadkarPN. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. J Neurochem, 113: 454–464, 2010.
375.
RotigA, deLonlayP, ChretienD, FouryF, KoenigM, SidiD, MunnichA, and RustinP. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet, 17: 215–217, 1997.
376.
RouaultTA, ZhangDL, and JeongSY. Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab Brain Dis, 24: 673–684, 2009.
377.
SaitsuH, NishimuraT, MuramatsuK, KoderaH, KumadaS, SugaiK, Kasai-YoshidaE, SawauraN, NishidaH, HoshinoA, RyujinF, YoshiokaS, NishiyamaK, KondoY, TsurusakiY, NakashimaM, MiyakeN, ArakawaH, KatoM, MizushimaN, and MatsumotoN. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet, 45: 445–449; 449e441, 2013.
378.
SakamotoN, OhshimaK, MonterminiL, PandolfoM, and WellsRD. Sticky DNA, a self-associated complex formed at long GAA center dot TTC repeats in intron 1 of the frataxin gene, inhibits transcriptions. J Biol Chem, 276: 27171–27177, 2001.
379.
SalahudeenAA, ThompsonJW, RuizJC, MaHW, KinchLN, LiQ, GrishinNV, and BruickRK. An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science, 326: 722–726, 2009.
380.
SalazarJ, MenaN, HunotS, PrigentA, Alvarez-FischerD, ArredondoM, DuyckaertsC, SazdovitchV, ZhaoL, GarrickLM, NunezMT, GarrickMD, Raisman-VozariR, and HirschEC. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A, 105: 18578–18583, 2008.
381.
SantambrogioP, BiasiottoG, SanvitoF, OlivieriS, ArosioP, and LeviS. Mitochondrial ferritin expression in adult mouse tissues. J Histochem Cytochem, 55: 1129–1137, 2007.
382.
SantosMM, de SousaM, RademakersLHPM, CleversH, MarxJJM, and SchilhamMW. Iron overload and heart fibrosis in mice deficient for both beta 2-microglobulin and Rag1. Am J Pathol, 157: 1883–1892, 2000.
SavittJM, DawsonVL, and DawsonTM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest, 116: 1744–1754, 2006.
385.
ScapagniniG, ButterfieldDA, ColombritaC, SultanaR, PascaleA, and CalabreseV. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal, 6: 811–818, 2004.
386.
ScapagniniG, VastoS, AbrahamNG, CarusoC, ZellaD, and FabioG. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol, 44: 192–201, 2011.
387.
SchmuckerS, MartelliA, ColinF, PageA, Wattenhofer-DonzeM, ReutenauerL, and PuccioH. Mammalian Frataxin: An Essential Function for Cellular Viability through an Interaction with a Preformed ISCU/NFS1/ISD11 Iron-Sulfur Assembly Complex. PLoS One, 6: e16199, 2011.
388.
SchneiderSA and BhatiaKP. Syndromes of neurodegeneration with brain iron accumulation. Semin Pediatr Neurol, 19: 57–66, 2012.
389.
SchroderJM. Ferritinopathy: diagnosis by muscle or nerve biopsy, with a note on other nuclear inclusion body diseases. Acta Neuropathol, 109: 109–114, 2005.
390.
SchroederEK, KelseyNA, DoyleJ, BreedE, BouchardRJ, LoucksFA, HarbisonRA, and LinsemanDA. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal, 11: 469–480, 2009.
391.
SchulzJB, DehmerT, ScholsL, MendeH, HardtC, VorgerdM, BurkK, MatsonW, DichgansJ, BealMF, and BogdanovMB. Oxidative stress in patients with Friedreich ataxia. Neurology, 55: 1719–1721, 2000.
392.
SeguinA, BayotA, DancisA, Rogowska-WrzesinskaA, AuchereF, CamadroJM, BulteauAL, and LesuisseE. Overexpression of the yeast frataxin homolog (Yfh1): contrasting effects on iron-sulfur cluster assembly, heme synthesis and resistance to oxidative stress. Mitochondrion, 9: 130–138, 2009.
393.
SenbongiH, LingF, and ShibataT. A mutation in a mitochondrial ABC transporter results in mitochondrial dysfunction through oxidative damage of mitochondrial DNA. Mol Gen Genet, 262: 426–436, 1999.
394.
SharmaN, BrandisKA, HerreraSK, JohnsonBE, VaidyaT, ShresthaR, and DebburmanSK. alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J Mol Neurosci, 28: 161–178, 2006.
395.
ShawGC, CopeJJ, LiLT, CorsonK, HerseyC, AckermannGE, GwynnB, LambertAJ, WingertRA, TraverD, TredeNS, BarutBA, ZhouY, MinetE, DonovanA, BrownlieA, BalzanR, WeissMJ, PetersLL, KaplanJ, ZonLI, and PawBH. Mitoferrin is essential for erythroid iron assimilation. Nature, 440: 96–100, 2006.
396.
SheftelAD, RichardsonDR, PrchalJ, and PonkaP. Mitochondrial iron metabolism and sideroblastic anemia. Acta Haematol, 122: 120–133, 2009.
397.
SheftelAD, ZhangAS, BrownC, ShirihaiOS, and PonkaP. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood, 110: 125–132, 2007.
398.
ShiHF, BenczeKZ, StemmlerTL, and PhilpottCC. A cytosolic iron chaperone that delivers iron to ferritin. Science, 320: 1207–1210, 2008.
399.
ShiR, ProteauA, VillarroyaM, MoukadiriI, ZhangL, TrempeJF, MatteA, ArmengodME, and CyglerM. Structural basis for Fe-S cluster assembly and tRNA thiolation mediated by IscS protein-protein interactions. PLoS Biol, 8: e1000354, 2010.
400.
ShimadaY, OkunoS, KawaiA, ShinomiyaH, SaitoA, SuzukiM, OmoriY, NishinoN, KanemotoN, FujiwaraT, HorieM, and TakahashiE. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J Hum Genet, 43: 115–122, 1998.
401.
ShirihaiOS, GregoryT, YuCN, OrkinSH, and WeissMJ. ABC-me: a novel mitochondrial transporter induced by GATA-1 during erythroid differentiation. EMBO J, 19: 2492–2502, 2000.
402.
ShvartsmanM, KikkeriR, ShanzerA, and CabantchikZI. Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol, 293: C1383–C1394, 2007.
403.
Sian-HulsmannJ, MandelS, YoudimMB, and RiedererP. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem, 118: 939–957, 2011.
404.
SigurdssonEM, BrownDR, AlimMA, ScholtzovaH, CarpR, MeekerHC, PrelliF, FrangioneB, and WisniewskiT. Copper chelation delays the onset of prion disease. J Biol Chem, 278: 46199–46202, 2003.
405.
SinghA, BeveridgeAJ, and SinghN. Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders. PLoS One, 6: e16804, 2011.
406.
SinghA, HaldarS, HorbackK, TomC, ZhouL, MeyersonH, and SinghN. Prion protein regulates iron transport by functioning as a ferrireductase. J Alzheimers Dis, 35: 541–552, 2013.
407.
SinghA, IsaacAO, LuoX, MohanML, CohenML, ChenF, KongQ, BartzJ, and SinghN. Abnormal brain iron homeostasis in human and animal prion disorders. PLoS Pathog, 5: e1000336, 2009.
408.
SinghA, KongQ, LuoX, PetersenRB, MeyersonH, and SinghN. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. PLoS One, 4: e6115, 2009.
409.
SinghA, MohanML, IsaacAO, LuoX, PetrakJ, VyoralD, and SinghN. Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis. PLoS One, 4: e4468, 2009.
410.
SinghA, QingL, KongQ, and SinghN. Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol Dis, 45: 930–938, 2012.
411.
SinghBN, ShankarS, and SrivastavaRK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol, 82: 1807–1821, 2011.
412.
SinghN, SinghA, DasD, and MohanML. Redox control of prion and disease pathogenesis. Antioxid Redox Signal, 12: 1271–1294, 2010.
413.
SipeJC, LeeP, and BeutlerE. Brain iron metabolism and neurodegenerative disorders. Dev Neurosci, 24: 188–196, 2002.
414.
SmithCD, ChebroluH, WeksteinDR, SchmittFA, JichaGA, CooperG, and MarkesberyWR. Brain structural alterations before mild cognitive impairment. Neurology, 68: 1268–1273, 2007.
415.
SmithMA, HarrisPLR, SayreLM, and PerryG. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A, 94: 9866–9868, 1997.
416.
SnyderAM, WangXS, PattonSM, ArosioP, LeviS, EarleyCJ, AllenRP, and ConnorJR. Mitochondrial ferritin in the substantia nigra in restless legs syndrome. J Neuropathol Exp Neurol, 68: 1193–1199, 2009.
417.
SoficE, LangeKW, JellingerK, and RiedererP. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett, 142: 128–130, 1992.
418.
SongN, JiangH, WangJ, and XieJX. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J Neurosci Res, 85: 3118–3126, 2007.
419.
StearmanR, YuanDS, Yamaguchi-IwaiY, KlausnerRD, and DancisA. A permease-oxidase complex involved in high-affinity iron uptake in yeast. Science, 271: 1552–1557, 1996.
420.
StockerR. Antioxidant activities of bile pigments. Antioxid Redox Signal, 6: 841–849, 2004.
421.
SubramanianP, RodriguesAV, Ghimire-RijalS, and StemmlerTL. Iron chaperones for mitochondrial Fe-S cluster biosynthesis and ferritin iron storage. Curr Opin Chem Biol, 15: 312–318, 2011.
422.
TaketaniS, KakimotoK, UetaH, MasakiR, and FurukawaT. Involvement of ABC7 in the biosynthesis of heme in erythroid cells: interaction of ABC7 with ferrochelatase. Blood, 101: 3274–3280, 2003.
423.
TapryalN, MukhopadhyayC, DasD, FoxPL, and MukhopadhyayCK. Reactive Oxygen Species Regulate Ceruloplasmin by a Novel mRNA Decay Mechanism Involving Its 3′-Untranslated Region: Implications in Neurodegenerative Diseases. J Biol Chem, 284: 1873–1883, 2009.
424.
TardiffDF, TucciML, CaldwellKA, CaldwellGA, and LindquistS. Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem, 287: 4107–4120, 2012.
425.
TheilEC. Ferritin: at the crossroads of iron and oxygen metabolism. J Nutr, 133: 1549s–1553s, 2003.
426.
TheilEC, ChenHJ, MirandaC, JanserH, ElsenhansB, NunezMT, PizarroF, and SchumannK. Absorption of iron from ferritin is independent of heme iron and ferrous salts in women and rat intestinal segments. J Nutr, 142: 478–483, 2012.
427.
TheilEC, LiuXFS, and ToshaT. Gated pores in the ferritin protein nanocage. Inorganica Chimica Acta, 361: 868–874, 2008.
428.
ThompsonK, MenziesS, MuckenthalerM, TortiFM, WoodT, TortiSV, HentzeMW, BeardJ, and ConnorJ. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res, 71: 46–63, 2003.
429.
TodorichB, ZhangXS, Slagle-WebbB, SeamanWE, and ConnorJR. Tim-2 is the receptor for H-ferritin on oligodendrocytes. J Neurochem, 107: 1495–1505, 2008.
430.
ToliyatT, JorjaniM, and KhorasaniradZ. An extended-release formulation of desferrioxamine for subcutaneous administration. Drug Deliv, 16: 416–421, 2009.
431.
TortiFM and TortiSV. Regulation of ferritin genes and protein. Blood, 99: 3505–3516, 2002.
432.
TortiSV, KwakEL, MillerSC, MillerLL, RingoldGM, MyamboKB, YoungAP, and TortiFM. The molecular-cloning and characterization of murine ferritin heavy-chain, a tumor necrosis factor-inducible gene. J Biol Chem, 263: 12638–12644, 1988.
433.
TrancikovaA, TsikaE, and MooreDJ. Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal, 16: 896–919, 2012.
434.
TrenorCC3rd, CampagnaDR, SellersVM, AndrewsNC, and FlemingMD. The molecular defect in hypotransferrinemic mice. Blood, 96: 1113–1118, 2000.
435.
TreuschS, HamamichiS, GoodmanJL, MatlackKE, ChungCY, BaruV, ShulmanJM, ParradoA, BevisBJ, ValastyanJS, HanH, Lindhagen-PerssonM, ReimanEM, EvansDA, BennettDA, OlofssonA, DeJagerPL, TanziRE, CaldwellKA, CaldwellGA, and LindquistS. Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science, 334: 1241–1245, 2011.
436.
TrinderD and BakerE. Transferrin receptor 2: a new molecule in iron metabolism. Int J Biochem Cell Biol, 35: 292–296, 2003.
437.
UlubayramK, KiziltayA, YilmazE, and HasirciN. Desferrioxamine release from gelatin-based systems. Biotechnol Appl Biochem, 42: 237–245, 2005.
438.
ValenteEM, Abou-SleimanPM, CaputoV, MuqitMM, HarveyK, GispertS, AliZ, Del TurcoD, BentivoglioAR, HealyDG, AlbaneseA, NussbaumR, Gonzalez-MaldonadoR, DellerT, SalviS, CortelliP, GilksWP, LatchmanDS, HarveyRJ, DallapiccolaB, AuburgerG, and WoodNW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304: 1158–1160, 2004.
439.
VashishtAA, ZumbrennenKB, HuangX, PowersDN, DurazoA, SunD, BhaskaranN, PerssonA, UhlenM, SangfeltO, SpruckC, LeiboldEA, and WohlschlegelJA. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science, 326: 718–721, 2009.
440.
Velasco-SanchezD, AracilA, MonteroR, MasA, JimenezL, O'CallaghanM, TondoM, CapdevilaA, BlanchJ, ArtuchR, and PinedaM. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum, 10: 1–8, 2011.
441.
VentiA, GiordanoT, EderP, BushAI, LahiriDK, GreigNH, and RogersJT. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann N Y Acad Sci, 1035: 34–48, 2004.
442.
VidalR, DelisleMB, and GhettiB. Neurodegeneration caused by proteins with an aberrant carboxyl-terminus. J Neuropathol Exp Neurol, 63: 787–800, 2004.
VidalR, MiravalleL, GaoXY, BarbeitoAG, BaraibarMA, HekmatyarSK, WidelM, BansalN, DelisleMB, and GhettiB. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci, 28: 60–67, 2008.
445.
Vives-BauzaC and PrzedborskiS. Mitophagy: the latest problem for Parkinson's disease. Trends Mol Med, 17: 158–165, 2011.
446.
von BernhardiR and EugeninJ. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal, 16: 974–1031, 2012.
447.
VulpeCD, KuoYM, MurphyTL, CowleyL, AskwithC, LibinaN, GitschierJ, and AndersonGJ. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet, 21: 195–199, 1999.
448.
WaldenWE, SeleznevaAI, DupuyJ, VolbedaA, Fontecilla-CampsJC, TheilEC, and VolzK. Structure of dual function iron regulatory protein 1 complexed with ferritin IRE-RNA. Science, 314: 1903–1908, 2006.
449.
WangF, WangX, YuanCG, and MaJ. Generating a prion with bacterially expressed recombinant prion protein. Science, 327: 1132–1135, 2010.
450.
WangJ, JiangH, and XieJX. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci, 25: 2766–2772, 2007.
451.
WangJA and PantopoulosK. Regulation of cellular iron metabolism. Biochem J, 434: 365–381, 2011.
452.
WangRH, LiCL, XuXL, ZhengY, XiaoCY, ZerfasP, CoopermanS, EckhausM, RouaultT, MishraL, and DengCX. A role of SMAD4 in iron metabolism through the positive regulation of hepicidin expression. Cell Metab, 2: 399–409, 2005.
453.
WangT, WangCY, ShanZY, TengWP, and WangZY. Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AbetaPP/PS1 transgenic mouse brain. J Alzheimers Dis, 29: 549–559, 2012.
454.
WatersBM and EideDJ. Combinatorial control of yeast FET4 gene expression by iron, zinc, and oxygen. J Biol Chem, 277: 33749–33757, 2002.
455.
WaxmanEA and GiassonBI. Induction of Intracellular Tau Aggregation Is Promoted by alpha-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau. J Neurosci, 31: 7604–7618, 2011.
456.
WeiX, RoettgerY, TanB, HeY, DodelR, HampelH, WeiG, HaneyJ, GuH, JohnstoneBH, LiuJ, FarlowMR, and DuY. Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. J Biol Chem, 287: 12858–12866, 2012.
457.
WeiY, MillerSC, TsujiY, TortiSV, and TortiFM. Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun, 169: 289–296, 1990.
458.
WeinrebO, AmitT, MandelS, KupershmidtL, and YoudimMB. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal, 13: 919–949, 2010.
459.
WeinrebO, AmitT, MandelS, and YoudimMB. Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr, 4: 283–296, 2009.
460.
WeissG. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta, 1790: 682–693, 2009.
461.
Wessling-ResnickM. Iron Homeostasis and the Inflammatory Response. Ann Rev Nutr, 30: 105–122, 2010.
462.
WestAR and OatesPS. Mechanisms of heme iron absorption: current questions and controversies. World J Gastroenterol, 14: 4101–4110, 2008.
463.
WhiteAR, BushAI, BeyreutherK, MastersCL, and CappaiR. Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. J Neurochem, 72: 2092–2098, 1999.
464.
WhiteRA, BoydstonLA, BrookshierTR, McNultySG, NsumuNN, BrewerBP, and BlackmoreK. Iron metabolism mutant hbd mice have a deletion in Sec15l1, which has homology to a yeast gene for vesicle docking. Genomics, 86: 668–673, 2005.
465.
WhitnallM and RichardsonDR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol, 13: 186–197, 2006.
466.
WhitnallM, Suryo RahmantoY, HuangML, SalettaF, LokHC, GutierrezL, LazaroFJ, FlemingAJ, St PierreTG, MikhaelMR, PonkaP, and RichardsonDR. Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A, 109: 20590–20595, 2012.
467.
WhitnallM, Suryo RahmantoY, SutakR, XuX, BeckerEM, MikhaelMR, PonkaP, and RichardsonDR. The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A, 105: 9757–9762, 2008.
468.
WicknerRB. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science, 264: 566–569, 1994.
469.
WicknerRB, MasisonDC, and EdskesHK. [PSI] and [URE3] as yeast prions. Yeast, 11: 1671–1685, 1995.
470.
WilksA, TorpeyJ, and Ortiz de MontellanoPR. Heme oxygenase (HO-1). Evidence for electrophilic oxygen addition to the porphyrin ring in the formation of alpha-meso-hydroxyheme. J Biol Chem, 269: 29553–29556, 1994.
471.
WillsAJ, SawleGV, GuilbertPR, and CurtisAR. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry, 73: 91–92, 2002.
WongA, YangJ, CavadiniP, GelleraC, LonnerdalB, TaroniF, and CortopassiG. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet, 8: 425–430, 1999.
474.
WongBS, BrownDR, PanT, WhitemanM, LiuT, BuXD, LiRL, GambettiP, OlesikJ, RubensteinR, and SyMS. Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem, 79: 689–698, 2001.
475.
WongCS, KwokJC, and RichardsonDR. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim Biophys Acta, 1739: 70–80, 2004.
476.
YeH and RouaultTA. Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry, 49: 4945–4956, 2010.
477.
YoonT and CowanJA. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J Am Chem Soc, 125: 6078–6084, 2003.
478.
YoonT and CowanJA. Frataxin-mediated iron delivery to ferrochelatase in the final step ofheme biosynthesis. J Biol Chem, 279: 25943–25946, 2004.
479.
ZarranzJJ, AlegreJ, Gomez-EstebanJC, LezcanoE, RosR, AmpueroI, VidalL, HoenickaJ, RodriguezO, AtaresB, LlorensV, Gomez TortosaE, del SerT, MunozDG, and de YebenesJG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol, 55: 164–173, 2004.
480.
ZeccaL, YoudimMB, RiedererP, ConnorJR, and CrichtonRR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci, 5: 863–873, 2004.
481.
ZhangS, WangJ, SongN, XieJ, and JiangH. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging, 30: 1466–1476, 2009.
482.
ZhangY, GaoJ, ChungKK, HuangH, DawsonVL, and DawsonTM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A, 97: 13354–13359, 2000.
483.
ZhouT, MaY, KongX, and HiderRC. Design of iron chelators with therapeutic application. Dalton Trans, 41: 6371–6389, 2012.
484.
ZhouXY, TomatsuS, FlemingRE, ParkkilaS, WaheedA, JiangJ, FeiY, BruntEM, RuddyDA, PrassCE, SchatzmanRC, O'NeillR, BrittonRS, BaconBR, and SlyWS. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A, 95: 2492–2497, 1998.
